Idiopathic Pulmonary Fibrosis study: ABBV-142
Official title Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
ClinicalTrials.gov ID: NCT07230288
What this study is testing
What is ABBV-142?
An investigational drug being studied as a potential treatment for idiopathic pulmonary fibrosis.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see how safe and well patients tolerate ABBV‑142 and whether it helps their lung disease. It also compares the drug to a placebo.
- Who it's for
- Adults who have been diagnosed with idiopathic pulmonary fibrosis.
- What's involved
- Participants will be randomly given either ABBV‑142 or a placebo for 52 weeks. They will visit a hospital or clinic regularly for medical exams, blood tests, side‑effect checks, and questionnaires. After the double‑blind period, some may continue the drug in an open‑label phase. All will be followed for 120 days after treatment.
- Time commitment
- The study lasts about 52 weeks of treatment plus a 120‑day follow‑up, with regular clinic visits throughout.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- \- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported...
You likely can't join if
- History of stroke within 6 months prior to screening
- In the opinion of the investigator, other clinically significant pulmonary abnormalities
- History of any malignancy up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ...
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Dothan, Alabama, United States
- Kissimmee, Florida, United States
- Champaign, Illinois, United States
- Ann Arbor, Michigan, United States
- Detroit, Michigan, United States
- Hannibal, Missouri, United States
- Philadelphia, Pennsylvania, United States
- Falls Church, Virginia, United States
- Richmond, Virginia, United States
- Nundah, Queensland, Australia
- Box Hill, Victoria, Australia
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Trois-Rivières, Quebec, Canada
- Montpellier, Herault, France
- Rennes, Ille-et-Vilaine, France
- Bobigny, Île-de-France Region, France
- Konstanz, Baden-Wurttemberg, Germany
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Dothan, Alabama, United States; Kissimmee, Florida, United States; Champaign, Illinois, United States; Ann Arbor, Michigan, United States; Detroit, Michigan, United States and 45 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.